Edition:
United States

Jaguar Health Inc (JAGX.OQ)

JAGX.OQ on NASDAQ Stock Exchange Capital Market

1.15USD
20 Jul 2018
Change (% chg)

$0.02 (+1.77%)
Prev Close
$1.13
Open
$1.12
Day's High
$1.23
Day's Low
$1.12
Volume
15,444
Avg. Vol
55,987
52-wk High
$14.85
52-wk Low
$1.07

Latest Key Developments (Source: Significant Developments)

Jaguar Health Inc Files For Non-Timely 10-K With U.S. SEC
Monday, 2 Apr 2018 05:19pm EDT 

April 2 (Reuters) - Jaguar Health Inc ::JAGUAR HEALTH INC FILES FOR NON-TIMELY 10-K WITH U.S. SEC.  Full Article

Jaguar Health Says Entered Securities Purchase Agreement With Chicago Venture Partners - SEC Filing​
Friday, 2 Mar 2018 12:48pm EST 

March 2 (Reuters) - Jaguar Health Inc ::JAGUAR HEALTH - ‍ON FEB 26, CO ENTERED SECURITIES PURCHASE AGREEMENT WITH CHICAGO VENTURE PARTNERS - SEC FILING​.JAGUAR HEALTH - ‍ PURSUANT TO AGREEMENT CO ISSUED TO CVP PROMISSORY NOTE IN AGGREGATE PRINCIPAL AMOUNT OF $2.2 MILLION FOR PURCHASE PRICE OF $1.6 MILLION.JAGUAR HEALTH - ‍ALSO ENTERED SECURITY AGREEMENT, PURSUANT TO WHICH CVP WILL RECEIVE SECURITY INTEREST IN SUBSTANTIALLY ALL OF CO'S ASSETS​.  Full Article

Jaguar Health Says Unit Napo Pharmaceuticals Signs Deal With Transition Patient Services To Establish Nationwide Pilot "Mytesi Direct" Program
Friday, 2 Mar 2018 09:12am EST 

March 2 (Reuters) - Jaguar Health Inc ::JAGUAR HEALTH - UNIT NAPO PHARMACEUTICALS SIGNS DEAL WITH TRANSITION PATIENT SERVICES TO ESTABLISH NATIONWIDE PILOT “MYTESI DIRECT” PROGRAM.JAGUAR HEALTH - UNDER DEAL TERMS, TRANSITION PATIENT SERVICES WILL OPERATE NATIONWIDE PILOT PROGRAM FOR MYTESI, EXPECTED TO BEGIN THIS MARCH.  Full Article

Jaguar Health Says Unit Entered Amendment To Note Purchase Agreement
Tuesday, 2 Jan 2018 04:44pm EST 

Jan 2 (Reuters) - Jaguar Health Inc ::JAGUAR HEALTH - ON DEC 29, 2017, UNIT ENTERED AMENDMENT TO NOTE PURCHASE AGREEMENT & NOTES WITH EACH OF PURCHASERS PARTY TO AGREEMENT DATED MARCH 1, 2017.JAGUAR HEALTH - ITS UNIT AMENDED ORIGINAL ISSUE DISCOUNT EXCHANGEABLE PROMISSORY NOTES PREVIOUSLY ISSUED TO PURCHASERS ON MARCH 1, 2017 & APRIL 27, 2017.JAGUAR HEALTH SAYS AMENDMENT LOWERS PRICE AT WHICH NOTES ARE EXCHANGEABLE FOR SHARES OF CO'S COMMON STOCK FROM $0.56/SHARE TO $0.20/SHARE - SEC FILING.JAGUAR HEALTH - AMENDMENT EXTENDS MATURITY DATE OF FIRST TRANCHE NOTES FROM DEC 1, 2017 TO FEB 15 & SECOND TRANCHE NOTES FROM JAN 27 TO APRIL 1.  Full Article

Jaguar Health ‍Enters Collaboration Agreement With SEED For Equilevia​
Thursday, 14 Dec 2017 10:09am EST 

Dec 14 (Reuters) - Jaguar Health Inc ::JAGUAR HEALTH INC - ‍ENTERED COLLABORATION AGREEMENT WITH SEED MENA BUSINESSMEN SERVICES FOR EQUILEVIA​.JAGUAR HEALTH- AS PER TERMS OF DEAL, CO WILL PAY SEED ONGOING PERCENTAGE OF REVENUE GENERATED FROM ANY CLIENTS OR PARTNERS INTRODUCED TO CO BY SEED.JAGUAR HEALTH INC - ‍ ACCORDING TO TERMS OF AGREEMENT, AGREED-UPON REVENUE PERCENTAGE INCREASES AFTER FIRST ONE-MILLION DOLLARS OF REVENUE​.  Full Article

Jaguar Health enters share purchase agreement
Monday, 27 Nov 2017 09:00am EST 

Nov 27 (Reuters) - Jaguar Health Inc ::JAGUAR HEALTH ENTERS SHARE PURCHASE AGREEMENT FOR 2 MILLION SHARES AND COMMON STOCK PURCHASE AGREEMENT RELATING TO A 10 MILLION SHARE EQUITY LINE OFFERING WITH L2 CAPITAL, LLC.JAGUAR HEALTH-ON NOV 24,CO ENTERED SHARE PURCHASE AGREEMENT WITH L2 CAPITAL AFTER WHICH CO SOLD 2 MILLION SHARES OF VOTING COMMON STOCK AT $0.25 PER SHARE ​.  Full Article

Jaguar Health ‍signs non-binding term sheet to issue note to Iliad Research
Wednesday, 8 Nov 2017 07:30am EST 

Nov 8 (Reuters) - Jaguar Health Inc :Jaguar health enters non-binding agreement of terms to issue a secured convertible note to iliad research and trading, l.p. (an affiliate of chicago venture partners, l.p.), as jaguar expands commercial efforts for mytesi.Jaguar health inc - ‍signed a non-binding term sheet to issue to iliad research and trading, l.p. Note of $1,375,000 for purchase price of $1,100,000​.Jaguar health inc - ‍note will bear interest at rate of 8.0% per annum, with a fixed conversion price of $0.52/share​.Jaguar health inc - ‍note will be due nine months after its issue date​.  Full Article

Jaguar Health files for resale or other disposition of up to 36 million shares of co
Friday, 20 Oct 2017 04:46pm EDT 

Oct 20 (Reuters) - Jaguar Health Inc ::Jaguar Health files for resale or other disposition of up to 36 million shares of co by the selling shareholders ‍​.  Full Article

Jaguar Health prices $4.25 million public offering of common stock
Friday, 29 Sep 2017 01:24pm EDT 

Sept 29 (Reuters) - Jaguar Health Inc :Jaguar health prices $4.25 million public offering of common stock.Says public offering of 21.3 million shares priced at $0.20 per share.  Full Article

Jaguar subsidiary Napo and Glenmark pharma sign agreement returning key rights in 141 countries to Napo
Monday, 25 Sep 2017 09:00am EDT 

Sept 25 (Reuters) - Glenmark Pharmaceuticals Ltd :Jaguar subsidiary Napo Pharmaceuticals and Glenmark Pharmaceuticals sign agreement returning key rights in 141 countries to Napo, solidifying Jaguar’s global commercial control of Mytesi (Crofelemer), Jaguar’s fda-approved human drug.Jaguar Health- Glenmark will continue to serve as CGMP-compliant commercial manufacturer of Crofelemer for Jaguar and Napo at its FDA-approved facilities in India.Jaguar Health- agreement also provides Napo with commercial rights to existing regulatory approvals for Crofelemer in Brazil, Ecuador, Zimbabwe & Botswana.  Full Article

BRIEF-Jaguar Health Files For Resale Of Up To 29.4 Mln Shares Common Stock By The Selling Shareholders

* JAGUAR HEALTH INC FILES FOR RESALE OF UP TO 29.4 MILLION SHARES COMMON STOCK BY THE SELLING SHAREHOLDERS - SEC FILING Source : https://bit.ly/2qOl6Fa Further company coverage: (Reuters.Briefs@thomsonreuters.com)